SCHEMBL4198080

SCHEMBL4198080

O=C1c2ccccc2C(=O)N1c1cc2cc[nH]c2cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.51
POLB P06746 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
GUSB P08236 1/20 0.40
GRM1 Q13255 3/20 0.39
AHR P35869 2/20 0.39
PDE10A Q9Y233 1/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
PMP22 Q01453 1/20 0.38
CASP1 P29466 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CTNNB1 P35222 1/20 0.36
WNT3A P56704 1/20 0.36
ALOX5AP P20292 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9848585 0.75 GPR84 (0.47) GPR84GRM1AHRGRM4
SCHEMBL803139 0.75 KMT2A (0.50) POLBESR1PDE10ACYP3A4KDM4E
SCHEMBL4194895 0.73 POLB (0.41) POLBESR1ESR2GRM1CYP3A4
SCHEMBL27260727 0.72 MAPT (0.46) POLBPDE10AKDM4EALDH1A1MAPT
SCHEMBL30354469 0.72 MAPT (0.46) POLBPDE10AKDM4EALDH1A1MAPT
SCHEMBL10626656 0.70 ESR1 (0.56) POLBESR1ESR2GRM1CYP3A4
SCHEMBL17104364 0.70 SMN1; SMN2 (0.47) POLBESR1ESR2CYP3A4NFKB1
SCHEMBL188052 0.70 GPR84 (1.00) GPR84POLBAHRKDM4EALDH1A1
SCHEMBL7751815 0.69 MGLL (0.61) POLBESR1ESR2CYP3A4NFKB1
SCHEMBL3914777 0.69 POLB (0.41) POLBESR1GRM1AHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239861-A1 QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2009-09-24 US disclosed
EP-1940825-A1 QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS Astra Zeneca AB (SE) 2008-07-09 EP disclosed
WO-2007034143-A1 QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239861-A1 QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS ABL1, ERBB2, CDK2 GPR84 2167/4885POLB 1601/4885ESR1 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.